Sanofi's Lixisenatide Gets Clean Bill Of Health On CV Safety, Heart Failure
This article was originally published in The Pink Sheet Daily
Executive Summary
ELIXA trial results show neither increased nor decreased risk of major adverse cardiovascular events; Sanofi's diabetes drug, still unapproved in the U.S., becomes the only GLP-1 receptor agonist with CV outcomes data.